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costs or total RA-related costs between patients starting rituximab, abatacept, or 
inﬂiximab. From a U.S. commercial payer perspective the costs associated with the 
three infused RA-biologics are similar.
PMS19
REAL-WORLD USE OF DULOXETINE FOR LOW BACK PAIN AND 
CHRONIC LOW BACK PAIN: TREATMENT PATTERN, DIRECT AND 
INDIRECT COSTS
Ivanova JI1, Birnbaum HG2, Kantor E2, Schiller M2, Johnstone B3, Faries D3, Risser R3, 
Swindle R3
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Eli Lilly 
and Company, Indianapolis, IN, USA
OBJECTIVES: Examine the real-world role of duloxetine versus other treatment for 
low back pain (LBP) and chronic LBP (CLBP). METHODS: There were 753 employees 
identiﬁed, ages 18 to 64 years, with ≥1 LBP diagnosis, per HEDIS speciﬁcations, and 
≥1 duloxetine prescription within a year after LBP diagnosis from a privately-insured 
claims database (2004–2007). Employees had continuous eligibility ≥6 months before 
(baseline) and ≥6 months after index duloxetine prescription (study period). Using 
propensity score matching, duloxetine-treated employees were matched to 753 LBP 
employees (controls) who initiated another pharmacological/non-invasive LBP treat-
ment in the same month from LBP diagnosis. A subset (n = 155 each) of matched 
employees with baseline CLBP (subsequent LBP diagnosis within 3–6 months after the 
initial LBP diagnosis) was also analyzed. McNemar tests were used to compare LBP 
treatment rates. Bias-corrected bootstrapping was used to compare direct (medical and 
drug) and indirect (workloss) costs from third-party payer perspective. RESULTS: 
During the 6-month study period, duloxetine-treated employees versus controls had 
signiﬁcantly lower rates of other pharmacological therapy (e.g., 44.0% vs. 56.4% 
narcotic opioids; 29.5% vs. 40.9% NSAIDs; all p < .001) and non-invasive therapy 
(22.3% vs. 38.7% chiropractic therapy; 18.9% vs. 38.0% physical therapy; 14.2% vs. 
27.0% exercise therapy; all p < .001). Back surgery rate was lower among duloxetine-
treated employees compared with controls (1.7% vs. 2.8%, respectively; p = 0.157). 
Duloxetine-treated employees versus controls had signiﬁcantly lower 6-month indirect 
costs ($1723 vs. $2198, p = 0.004) and lower direct costs ($4935 vs. $5649, p = 0.267). 
Sensitivity analysis using multivariate analysis conﬁrmed the results. Among CLBP 
patients, duloxetine-treated employees versus controls had a lower rate of surgery 
(1.3% vs. 5.2%, p = 0.058), direct ($5519 vs. $7066, p = 0.345) and indirect costs 
($1996 vs. $2612, p = 0.191). CONCLUSIONS: Duloxetine treatment in LBP and 
CLBP employees versus other non-surgical treatment was numerically associated with 
reduced rates of non-surgical therapies, surgery, and lower direct and indirect costs.
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COST EFFECTIVENESS ANALYSIS OF MANAGING CHRONIC GOUT 
WITH FEBUOXSTAT (ULORIC) VERSUS ALLOPURINOL (ZYLOPRIM)
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OBJECTIVES: To evaluate the cost effectiveness of febuoxstat compared with allo-
purinol for the management of chronic gout in the United States. METHODS: Using 
the FACT trial that compared febuoxstat with allopurinol in managing chronic gout, 
a “backward induction model” was designed using a hypothetical cohort of male 
patients in the US aged 40 to 80 years. Model estimates were taken from the trial and 
existing literature. The trial demonstrated equivalent efﬁcacy for these drugs but the 
probability of a patient attaining Allopurinol Hypersensitvity Syndrome (AHS) was 
inputted and evaluated. AHS probability and total costs were obtained from literature, 
and utility value was obtained from expert opinion. These values were used for the 
base case analysis. Using a societal perspective, QALYs and costs were calculated using 
backward induction to generate lifetime incremental cost effectiveness. All costs were 
reported as 2009 US dollars, after being inﬂated using the medical component of the 
CPI. Life expectancy, QALYs, and costs were discounted at a rate of 3%. RESULTS: 
Using a societal cost effectiveness threshold of US $150,000/QALY, managing chronic 
gout using febuoxstat daily is cost effective for males aged 55 to 75 years. It becomes 
cost ineffective for males aged 40 to 50 years. Febuoxstat contributed to greater 
QALYs for all patients with AHS at 2%. A one way sensitivity analysis was performed 
using the 55 year old male patient as a base case comparison with an ICER of US 
$110,701/QALY to test uncertainties. If AHS is not considered in this model, then 
febuoxstat will be to cost ineffective throughout this analysis. CONCLUSIONS: Cur-
rently, febuoxstat is more expensive, and since they are both equally efﬁcacious, 
allopurinol should be recommended as ﬁrst line therapy. Febuoxstat can be used as a 
cost effective alternative in certain age groups, if AHS occurs.
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COST—EFFECTIVENESS OF RITUXIMAB VS ADALIMUMAB IN THE 
TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Bynum LA, Joshi N
University of Mississippi, University, MS, USA
OBJECTIVES: To determine the cost-effectiveness of Rituximab (Rituxan) in com-
parison to the standard treatment of Adalimunab (Humira) for patients with moderate 
to severe rheumatoid arthritis. METHODS: A decision analytic model was carried out 
comparing the effectiveness and treatment costs of two treatments consisting of the 
standard care (Adalimumab) or the alternative care (Rituximab). Four outcome groups 
were deﬁned for each alternative: Effective with or without adverse events and Not 
Effective with or without adverse events. Results from clinical trials and pertinent 
literature were used to derive the model inputs. A published equation was used to 
predict quality-adjusted life years (QALYs) from the Health Assessment Questionnaire 
(HAQ) disability index. The HAQ-DI assesses the extent of the patient’s functional 
ability and has been extensively used in clinical settings. The HAQ-DI is sensitive to 
change and is a good predictor of future disability and costs. Costs included the medi-
cation acquisition cost, the physician and monitoring costs as well as the average 
adverse drug events costs. All costs were expressed in 2009 US dollars. A sensitivity 
analysis was undertaken in order to assess the uncertainty surrounding calculated 
QALY scores. RESULTS: Based on the outcome estimates of the randomized clinical 
trials as well as the acquisition, physician, monitoring and adverse drug event costs. 
The study ﬁndings indicate that the clinical beneﬁts on the change in QALY scores 
resulting in an incremental cost of $66,123.00. The sensitivity analysis conﬁrmed the 
results to be robust and are not affected by uncertainty. CONCLUSIONS: This study 
suggests that Adalimumab is more costly and less effective than Rituximab. These 
results indicate that Rituximab should be utilized for the treatment of moderate to 
severe rheumatoid arthritis.
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THE COST-EFFECTIVENESS OF PREGABALIN (LYRICA®) IN THE 
TREATMENT OF SEVERE FIBROMYALGIA IN THE UNITED STATES
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OBJECTIVES: Fibromyalgia is a chronic condition manifesting with widespread pain, 
non-restorative sleep, fatigue and cognitive dysfunction. Fibromyalgia imposes high 
costs due to work loss and medical resource use. We built a decision-analytic model 
to assess the cost-effectiveness of treating severe ﬁbromyalgia with pregabalin. 
METHODS: Patients considered had Fibromyalgia Impact Questionnaire scores >59 
and pain scores >6.5 at baseline. Pregabalin 450 mg and 300 mg were compared to 
placebo, duloxetine, gabapentin, tramadol, milnacipran and amitriptyline. Patient 
response was assessed after 12 weeks of therapy: responders entered a long term model 
in which they maintained response, lost response, or dropped out. Response rates for 
pregabalin and placebo were derived from a pooled analysis of 3 randomized trials: 
response was deﬁned as a ≥30% improvement over baseline pain score and patient 
global impression of change rated much or very much improved. Response rates for 
other comparators were obtained from a systematic review of randomized controlled 
studies. Longer term outcomes were derived from an open-label follow-up extension 
of a randomised pregabalin study. The primary effectiveness endpoint was mean days 
in response. Resource use was estimated from published studies. Costs were calculated 
from a societal perspective including health care costs and productivity loss. RESULTS: 
At 12 weeks, people treated with pregabalin achieved 28 days in response compared 
to 14 with placebo. Total cost per patient was $402 higher with pregabalin 300 mg 
and $989 lower with pregabalin 450 mg compared to placebo. At 1 year, pregabalin 
300 mg was less costly and more effective than placebo, duloxetine, milnacipran or 
gabapentin: the incremental cost per additional day in response compared to tramadol 
and amitriptyline was $43 and $10 respectively. Pregabalin 450 mg gave reduced costs 
and more response days than all comparators. CONCLUSIONS: Pregabalin was 
found to be an effective therapy for severe ﬁbromyalgia patients and was cost-saving 
compared to most other ﬁbromyalgia treatments.
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OBJECTIVES: to perform economic evaluation of adalimumab + methotrexate vs 
rituximab + methotrexate and inﬂiximab + methotrexate in patients with rheumatoid 
arthritis resistant to traditional methods of treatment in Russian health care system. 
METHODS: the modeled study was performed. Data on dosing regimen, efﬁcacy and 
safety of biologics were extracted from studies ARMADA, DANCER, and ATTRACT. 
Effect was measured in proportion of patients receiving this combination achieved 
ACR 20/50/70. Cost of treatment with biologics combined with methotrexate for 24 
weeks and cost-effectiveness ratio (CER) were calculated from the Russian reimburse-
ment system point of view. RESULTS: adalimumab is more effective in patients 
achieved ACR 20 (67, 54, and 50% of patients receiving adalimumab, rituximab, and 
inﬂiximab accordingly achieved ACR 20), ACR 50 (55, 34, and 27% accordingly), 
and it is more effective that inﬂiximab and has nearly equal efﬁcacy with rituximab 
in patients achieved ACR 70 (27, 30, and 8% accordingly). The cost of treatment was 
682,229.06 rubles for adalimumab + methotrexate, 651,876.66 rubles for inﬂiximab 
+ methotrexate, and 472,906.20 rubles for rituximab + methotrexate. CER for effec-
tiveness criteria “achieving ACR 20” for adalimumab was 1,018,252.33. It was lower 
than for inﬂiximab (1,303,753.32), but higher than for rituximab (875,752.22). CER 
for effectiveness criteria “achieving ACR 50” was 1,240,416.47, 1,390,900.59, and 
2,414,358.00 accordingly, and CER for “achieving ACR 70” was 2,526,774.30, 
2,364,531.00, and 8,148,458.25 accordingly. Incremental CER for adalimumab was 
1,610,175.85 / 996,775.52 / 2,990,326.57 rubles for one patient achieved ACR 
20/50/70 compared to rituximab. CONCLUSIONS: adalimumab, used as ﬁrst line of 
therapy with biological drugs, is more economically effective in patients with rheu-
matoid arthritis resistant to standard therapy, than inﬂiximab. Rituximab seems to be 
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more economically effective alternative drug but it can be used only as second or third 
line of treatment with biological drugs according to Russian standards of rheumatoid 
arthritis’ management.
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COST-EFFECTIVENESS COMPARATIVE ANALYSIS OF 
BISPHOSPHONATES FOR THE TREATMENT OF POST-MENOPAUSAL 
OSTEOPOROSIS
Ousterhout MM, Blaser DA, Gagnon J
UMass Medical School, Shrewsbury, MA, USA
OBJECTIVES: This study seeks to compare the cost-effectiveness of bisphosphonates 
for the treatment and prevention of post-menopausal osteoporosis (PMO). 
METHODS: A literature review was conducted to obtain all relevant articles pub-
lished through the end of 2009 that evaluate the cost-effectiveness of bisphosphonates 
for the treatment and prevention of PMO. PubMed and the Cochrane Database 
were used to search for the terms “bisphosphonates” and “cost-effectiveness.” 
Articles were limited to those evaluating at least one of the four products with an 
indication approved by the United States Food and Drug Administration for PMO: 
alendronate, ibandronate, risedronate, or zoledronic acid. Articles focusing on screen-
ing efforts, or evaluating the treatment of men, glucocorticoid-induced osteoporosis, 
or cancer-related bone complications were excluded. A manual review of the included 
articles’ references was also performed. RESULTS: The literature search resulted in 
189 articles of which 18 met the criteria for inclusion in this evaluation. Of these 
18 studies, many examined the use of more than one bisphosphonate, therefore, the 
total number of comparisons identiﬁed for alendronate, ibandronate, risedronate, 
and zoledronic acid were 13, 3, 8, and 1, respectively. The incremental cost- 
effectiveness ratios obtained from this analysis varied greatly for all included agents: 
alendronate ranged from −$25,296.12 (cost-savings) to $934,883.71; ibandronate 
from $10,354.68 to $15,023.90; risedronate from $1,468.75 to $241,410.15; and 
zoledronic acid from $1,791.42 to $2,205.39. These results varied based on the 
included women’s age and underlying risk factors, the speciﬁc costs accounted for 
in each analysis, and the total duration of treatment. CONCLUSIONS: Bisphospho-
nates represent cost-effective treatment options for the prevention and treatment of 
PMO. Given the evidence available, it is difﬁcult to determine whether one agent 
is conclusively more cost-effective than another for this indication. Further studies 
directly comparing bisphosphonates should be conducted to evaluate their compara-
tive cost-effectiveness.
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A PHARMACOECONOMIC REVIEW OF ECONOMIC ANALYSES OF 
BIOLOGIC THERAPIES IN PATIENTS WITH ANKYLOSING SPONDILITIS
Atreja N1, Kamal K2, Patel BB2
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OBJECTIVES: To conduct a systematic review of economic analyses of biologic 
therapies in patients with ankylosing spondylitis (AS) METHODS: A systematic 
literature search was conducted by one researcher from January, 2000 to January, 
2009 using Pubmed, Evidence-Based Medical Reviews, and Medline databases to 
identify all economic studies of biologic therapies in AS. Search key terms included 
ankylosing spondylitis, biologics, Adalimumab, Inﬂiximab, Etanercept, cost, phar-
macoeconomics, and combination of search terms. The Quality of Health Economic 
Studies (QHES) instrument was used to assess the quality of economic studies 
included in the ﬁnal review. RESULTS: The initial search yielded nine studies out 
of which three review studies were excluded. The remaining six studies compared 
the biologics Etanercept, Inﬂiximab, and Adalimumab against comparators such as 
NSAIDs and placebo. One study employed a cost-effective analysis (cost/BASDAI 
score), while the remaining studies employed cost-utility analysis (cost/QALYs). Inf-
liximab and Adalimumab were found to be cost-effective compared to NSAIDs and 
placebo with a CE ratio of $10,000/QALY (US) and £5,093/QALY (UK). A com-
binational therapy of Etanercept and NSAIDs was found to be cost-effective (£ 
25,000, UK) versus NSAIDs. A combination of Inﬂiximab and Etanercept versus 
NSAIDs alone was not cost-effective (Etanercept 342,494/QALY, Inﬂiximab 367,207/
QALY). CONCLUSIONS: In most studies the CE ratio of Adalimumab and Inﬂix-
imab was below the accepted threshold of $50,000/QALY (US) and £25,000/ QALY 
(UK). However, a study conducted in the The Netherlands did not approve the 
combinational use of Inﬂiximab and Etanercept in the treatment of AS, since 
the total treatment cost was higher than the accepted threshold of 318,000/QALY. 
The results in different studies varied because of underlying study assumptions and 
different study methodologies. Clinical decision-makers must take into account 
country and model-speciﬁc parameters in order to make decisions on the use of 
biologics in AS.
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COSTS OF VERTEBROPLASTY AND KYPHOPLASTY FROM THE 
HOSPITAL PERSPECTIVE
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OBJECTIVES: The clinical burden associated with osteoporotic vertebral body com-
pression fracture (VCF) has been well documented in the literature. Less information 
is available on the economics of interventions for treatment of VCF—including ver-
tebroplasty and kyphoplasty—which are reported to be equally efﬁcacious options for 
patients suffering from this debilitating condition. This study seeks to quantify hospital 
costs associated with vertebroplasty and kyphoplasty. METHODS: Analysis of hos-
pital discharge and billing records extracted from the Premier Perspective™ database, 
2007–2008. The Premier database contains clinical and ﬁnancial information from 
over 600 hospitals. Independent-sample t tests were used to test for between-group 
differences in total and department-speciﬁc direct medical costs incurred during the 
index inpatient or outpatient procedure. RESULTS: A total of 3617 patients received 
vertebroplasty (64% inpatient and 36% outpatient) and 8,118 received kyphoplasty 
(54% inpatient and 46% outpatient) for treatment of VCF. Patients in the vertebro-
plasty group had a mean age of 78, and patients in the kyphoplasty group had a mean 
age of 76. More patients in the vertebroplasty group (14.5%) had an APR-severity 
rating of “major” or “extreme” than patients in the kyphoplasty group (9.5%). Mean 
total inpatient costs were $9,837 for vertebroplasty compared to $13,187 for kypho-
plasty (p < 0.0001). Mean total outpatient costs were $3,319 for vertebroplasty 
compared to $8,100 for kyphoplasty (p < 0.0001). Adjustments to control for differ-
ences in age, sex, admission status, and disease severity accentuate these differences. 
CONCLUSIONS: Compared to kyphoplasty, vertebroplasty is a cost-minimizing 
option for treatment of VCF, reducing hospital costs by nearly $5000 for outpatient 
procedures and by more than $3000 for inpatient procedures. These differences 
occurred despite older age and greater disease severity for patients in the vertebro-
plasty group. Further research is necessary to evaluate the incremental cost effective-
ness of treatment options for VCF.
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THE COMMON PRACTICE OF ANTI-TNF PRESCRIPTION AND 
DISPENSING CONDITIONS
Andrieu S1, Ripert M2, Meunier N2, Camara Raynaud C3
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OBJECTIVES: The objective was to compare Etanercept and Adalimumab in terms 
of adequacy of recommended indications and of the health care costs. METHODS: 
This survey of cost minimization was performed by an ofﬁce based pharmacist panel 
answering to a questionnaire at the moment of the delivery of one among two ambula-
tory biologics, Etanercept and Adalimumab. RESULTS: The results show that these 
biologics are mainly prescribed in rheumatology, 94% and 79% for Etanercept and 
Adalimumab respectively. The prescriptions are consistent with recommended indica-
tions for both products. In rheumatology, the retailing of consumption by pathology 
is closed for the two treatments. The follow of treatment scheme and of the associated 
costs have been realized only for the adult rheumatologic indications. At 93.8%, 
“Etanercept 50 mg” is prescribed at the recommended dosage. In 2.2 % of cases, the 
dosage increased at two injections per week and decreased at one injection all 2 weeks 
in 2.5 % of cases. For Adamimumab, 82.6 % treatments followed the recommended 
dosage, 3.6 % at an inferior dosage and 13.8 % at a superior dosage with one or two 
injections per week. The differential between the recommended treatment scheme and 
the common practice have a direct impact on the annual treatment cost. The health 
care costs with Etanercept appeared less expensive. The mean annual cost per patient 
is of 312,566 with Etanercept and of 316,252 with Adalimumab. CONCLUSIONS: 
This survey demonstrates that the health care cost is 29% superior with Adalimumab. 
The health care with Etanercept seems to have a better stability of the recommended 
treatment scheme.
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COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA 
INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS 
USING A MARKOV MODEL
Nguyen CM, Mendes M, Bounthavong M, Christopher M, Morreale AP
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OBJECTIVES: To determine which tumor necrosis factor-alpha (TNF-alpha) inhibitor 
is the most cost-effective agent for the treatment of rheumatoid arthritis. METHODS: 
A Markov model was designed to analyze the cost-utility of certolizumab, etanercept, 
adalimumab and golimumab versus inﬂiximab (with methotrexate) for the treatment 
of moderately to severely active rheumatoid arthritis from a U.S. health care payer 
perspective. A cohort of 10,000 patients was simulated using half-cycle correction 
with a cycle length of three months for a total of ﬁve years. The probability of achiev-
ing ACR70, serious infections, and hospitalization were based on data from published 
literature and assumed to follow a beta distribution. Utility scores were based on a 
published report using a visual analog scale. Costs were adjusted for 2009 U.S. dollars 
using the medical consumer price index and a discount rate of 3% per annum. Cost 
and utility scores were assumed to follow a gamma distribution. Probabilistic sensitiv-
ity analysis (PSA) was performed to test the robustness of the base-case model. 
RESULTS: Certolizumab, etanercept, adalimumab and golimumab were dominant 
compared to inﬂiximab with incremental cost-effectiveness ratios (ICERs) of 
−$101,377.60, −$137,606.34, −$102,689.18, and −$63,415.60/additional QALY 
gained, respectively. The cost-effectiveness ratios of certolizumab, etanercept, adalim-
umab, golimumab, and inﬂiximab were $6325.62, $6467.41, $6595.43, $6903.74, 
and $7508.16, respectively. Certolizumab resulted in the lowest cost and highest gain 
in QALYs compared to all comparators. In the PSA, there was a higher proportion 
of ICERs that were cost-effective with certolizumab (91.06%), etanercept (85.89%), 
adalimumab (84.67%), and golimumab (79.23%) when compared to inﬂiximab at a 
willingness-to-pay (WTP) of $60,000. The acceptability curve showed that certoli-
zumab had a higher probability of being cost-effective compared to all other compara-
tors at a WTP of $60,000/additional QALY gained. CONCLUSIONS: At a $60,000 
